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Abstract
Medical treatment in symptomatic patients with hypertrophic obstructive cardiomyopathy
aims to reduce the outflow tract gradients, and to improve diastolic dysfunction and rhythm
disorders. Surgical myectomy is the standard treatment in patients with drug refractory
symptoms. Since the early 1990s, dual-chamber (DDD)-pacemaker implantation and
percutaneous transluminal septal myocardial ablation by alcohol-induced septal branch
occlusion have widened treatment options in this subgroup of patients. An overview of
medical and interventional treatment is presented.
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AV = atrioventricular; DDD-pacemaker = dual-chamber pacemaker; HCM = hypertrophic cardiomyopathy; HOCM = hypertrophic obstructive
cardiomyopathy; LAD = left anterior descending coronary artery; PET = positron emission tomography; PTSMA = percutaneous transluminal septal
myocardial ablation; SAM = systolic anterior movement of the mitral valve.
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Introduction
Hypertrophic obstructive cardiomyopathy (HOCM) was
described in the late 1950s as a new entity of myocardial
hypertrophy with dynamic left ventricular outflow tract
obstruction. Hypertrophic cardiomyopathy (HCM), in the
meantime, was described as a disease of the sarcomere
[1,2]. Up to now, 10 loci of mutations have been found.
Obstruction is mainly seen in the subaortic region associ-
ated with a systolic movement of the mitral valve appara-
tus, and about 5% of the patients present mid-cavitary
obstruction [1]. Typical symptoms are dyspnea, angina
pectoris, stress-induced syncope, and increased risk for
sudden cardiac death in some patients. HOCM is the
most frequent cause of exertional syncope or sudden
cardiac death in younger patients (<30 years) [3].
Treatment options
Treatment of symptomatic patients with HOCM aims to
improve functional disability, to reduce the extent of the
outflow tract obstruction, and to improve diastolic filling.
Furthermore, treatment of arrhythmias and prophylaxis of
bacterial endocarditis must be considered.
Administration of negatively inotropic drugs is the treat-
ment of first choice, but up to 10% of patients with marked
outflow tract obstruction have severe symptoms unrespon-
sive to medical therapy [4]. Only in this group may a more
interventional approach be considered in order to improve
hemodynamic function and clinical status. A direct compar-
ison of medical treatment and percutaneous septal abla-
tion, which was primarily performed in 1995 [5], has
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therefore not been performed up to now. The reported
number of drug-refractory patients may be influenced by
referral bias. Where patients are referred for interventional
treatment in our own group, about two-thirds require active
treatment either by alcohol ablation or surgical myectomy,
whereas modification of medical treatment results in symp-
tomatic improvement in one-third of the patients.
Medical treatment
Negatively inotropic drugs (beta-blockers, calcium antago-
nists of verapamil type, disopyramid, and cibenzoline) are
used to decrease outflow tract obstruction [6–14].
Outflow tract gradient reduction >50% at rest and provo-
cation has been described by administration of verapamil
[6–8]. This drug is the predominantly medical therapy of
first choice in Germany, whereas Anglo-American col-
leagues are more restrictive due to the potential vasodilat-
ing effect of calcium anatagonists that may lead to an
increase of the outflow tract gradient. Pulmonary edema
and sudden death have been described [8]. Therefore,
verapamil should only be used with short-term echoardio-
graphic monitoring of outflow tract gradient. Verapamil has
been proved to improve left ventricular filling properties in
patients with predominant diastolic dysfunction [7]. Per-
sonal observations with induction of high-grade atrio-
ventricular (AV) blocks after verapamil treatment underline
the importance of rhythmogenic monitoring.
Administration of beta-blockers reduces left ventricular
outflow tract obstruction [9–11], and they have a special
effect in patients with latent obstruction (eg low resting
and high provocable gradients). Beta-blockers should
especially be the drug of first choice in patients with addi-
tional coronary artery disease.
Anglo-American authors prefer disopyramid, a class 1A
anti-arrhythmic drug, in doses up to 800 mg/day [1,12,
13]. Anticholinergic side effects especially limit the use of
hemodynamically effective doses. Another limitation is the
decrease of hemodynamic benefit by time. German col-
leagues are restrictive in administration of disopyramid
due to the reported pro-arrhythmogenic side effect of
class I anti-arrhythmic drugs in patients with coronary
artery disease. Limited experiences exist with the use of
another class I anti-arrhythmic drug, cibenzoline, a further
restriction of which is limited availability [14].
In symptomatic patients with hypertrophic cardiomyopathy
without outflow tract gradient at rest and provocation
afterload, reduction with angiotensin-converting enzyme
inhibitors may improve clinical symptoms. But echocardio-
graphic monitoring is required to exclude development of
obstruction at long-term afterload reduction.
Patients with hypertrophic cardiomyopathy and atrial fibril-
lation generally require anticoagulation for preventing
embolic events. Cardioversion and preservation of sinus
rhythm after successful cardioversion is predominantly
performed with administration of amiodarone, the positive
effects of which in patients with ventricular tachycardia are
well described [15]. An actual observational study dis-
cussed the possible positive effect of implantation of a
defibrillator in this subgroup [16].
HOCM carries increased risk of endocarditis and requires
standard prophylaxis according to the guidelines of
cardiac societies. Although >50% of patients with the
non-obstructive form of HCM have morphologic changes
of the mitral valve apparatus [17], this group of patients
seems to carry no increased risk of endocarditis during
long-term observational studies so prophylaxis seems not
to be required in this condition [18].
Percutaneous transluminal septal myocardial
ablation
An important number of patients with HOCM suffer from
clinical symptoms like dyspnea, angina, and exercise-
induced syncope despite intensive anti-obstructive
medical treatment. Furthermore, long-lasting disease
increases the risk of atrial fibrillation, with its negative
impact on clinical symptoms and potential embolic events.
Outflow tract gradient reduction should be achieved in
this group of patients via a more active treatment.
Because of the favorable hemodynamic and clinical
results of surgical myectomy [19–22], with its increased
surgical risk, a percutaneous approach of reduction of
hypertrophied septal muscle bulge by induction of a local-
ized septal infarction was considered in the late 1980s.
An alcohol-induced septal branch ablation procedure had
already been described at that time as a therapy of ven-
tricular tachycardia [23]. Sigwart was the first to report
successful non-surgical myocardial reduction after occlu-
sion of the septal branch using 96% alcohol in three
patients [5].
Several modifications of the ablation technique aim to
improve the identification of the target septal branch with
optimization of the hemodynamic effect and reduction of
complications [24–26]. Alcohol ablation is performed by
injection of 2–4 ml absolute alcohol in the target septal
branch. Identification of the septal branch by myocardial
contrast echocardiography turned out to be the standard
technique. One to two milliliters of echo contrast medium
(Levovist®, Schering, Berlin, Germany) were administered
prior to alcohol injection through the central lumen of the
balloon catheter under color Doppler echocardiographic
monitoring. Injection into the optimal septal branch leads
to complete coverage of the echo contrast marked septal
area, on the one hand, and of the color Doppler estimated
area of maximal flow acceleration as well as the area of
systolic anterior movement of the mitral valve (SAM) septalc
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contact on the other, without opacification of any other
cardiac structure. The amount of injected alcohol depends
on the acute hemodynamic effect and the echocardio-
graphically estimated size of the contrasted septal area.
Furthermore, the reflux of contrast medium (and thus of
alcohol) into the left anterior descending coronary artery
(LAD) should be excluded. This is of vital importance to
avoid LAD damage and thus an infarction of the anterior
wall. From the interventional standpoint, a slightly over-
sized balloon should be used and kept inflated 10 min
after the last alcohol injection.
Accepted indications for percutaneous transluminal septal
myocardial ablation (PTSMA) are symptomatic patients
classified as greater than New York Heart Association
class III/Canadian Cardiovascular Society III despite drug
therapy, or with important side effects of medication.
Patients with less severe symptoms were only treated if
they had high outflow tract gradients (³50 mmHg at rest,
or ³30 mmHg at rest and 100 mmHg under stress) and
documented high-risk factors for sudden cardiac death
[3,6] or objective reduction of exercise capacity. It should
be taken into consideration, however, that up to now only
few data suggest that gradients have an impact on the risk
for sudden death [27]. Patients with previous but hemody-
namically unsuccessful surgical myectomy or DDD-pace-
maker implantation can also be treated. Patients with
concomitant cardiac diseases indicating surgery, for
example extensive coronary artery disease, valvular
disease, and morphologic changes of the mitral valve as
well as papillary muscle responsible for gradient formation
or mitral regurgitation, should not be treated intervention-
ally. Furthermore, hypertrophic cardiomyopathy without
resting, as well as provocable outflow tract gradient, is a
clear contraindication for PTSMA. Alcohol should not be
injected in the presence of echocardiographically failed
identification of a target septal branch, opacification of any
cardiac structure other than the target septal area by echo
contrast media, and unstable balloon position with risk of
alcohol reflux during injection.
Outflow tract gradient reduction can be acutely achieved
in about 90% of the patients. Because of post-ablation
remodeling and further shrinkage of the ablated area, it is
not necessary to abolish the gradient. Further gradient
reduction can be observed in >50% of the treated
patients. The outflow tract gradient reduction lasts at least
1 year. The prerequisite for this remodeling is optimization
of the alcohol depot in size and location, which results in
smaller infarct size, probably with reduced risk of late left
ventricular dilatation, and reduced complication rates. The
author’s experiences have shown that this optimization
can be achieved using an echo contrast guided approach
that reduced the need for pacemaker implantation due to
postinterventional trifascicular block from 17 to 5% [28].
The in-hospital mortality of 1.1% in our group is comparable
with surgical results. Mortality rates up to 3.5% have,
however, been reported [29]. As in myectomy, elderly
patients and patients with functional class IV showed
increased risk of postinterventional complication [30,31].
This finding should result in an improved and prolonged
postinterventional monitoring in this group of patients.
Further reported complications such as dissections of the
LAD or necrosis of other than the septal area underline the
importance of an experienced interventionalist and
echocardiographer who is able to interpret the on-line
echo contrast studies.
Clinical and hemodynamic follow-up studies for up to
4 years have shown no increased risk of sudden death or
rhythmogenic complications [32,33]. Furthermore, septal
perforation has not been reported during follow-up. The
most important finding is the ongoing symptomatic
improvement of the treated patients, which is proved by
objective measurements during exercise tests [34]. Mea-
surements of diastolic function have shown improvement
of this second hemodynamic consequence of the disease
[25]. The most important finding from the hemodynamic
standpoint is the continuing and increasing reduction of
the left ventricular outflow tract gradients (Figure 1) [35].
This reduction should be viewed as an expression of
postinterventional remodeling following an induced septal
infarction, analogous to the remodeling following acute
myocardial infarction. These findings also underline our
strategy to induce septal necrosis by alcohol ablation that,
while sufficiently large, should be as small as possible.
Remodeling after PTSMA also results in reduction of both
the ventricular septal thickness and the left ventricular
posterior wall thickness [25,35]. Similar findings have
Figure 1
Left ventricular outflow tract (LVOT) gradients before (Pre), after
(Post), and 3 and 12 months (Mo.) following percutaneous septal
ablation in symptomatic patients with hypertrophic cardiomyopathy.been reported after surgical myectomy [36]. Furthermore,
some groups report reduction of both left ventricular end
diastolic pressure and mean pulmonary arterial pressure
[25,35]. The author’s studies found a decrease of left
atrial diameter [35] and maximal coronary blood flow esti-
mated by positron-emission tomography (PET) investiga-
tions. Furthermore, most of the patients with abnormal
blood pressure response at baseline showed normaliza-
tion at 3 months.
Only individual patients with HCM and mid-ventricular
obstruction have been treated up to now. Especially,
echocardiographic monitoring of PTSMA gives the
opportunity to treat patients with this unfavorable
anatomy for surgical myectomy. Differential indication for
surgical and non-surgical myectomy should be worked
out in the future by cooperation of all specialists involved
in the field of HOCM.
In summary, PTSMA is a promising treatment option in
symptomatic patients refractory to medical treatment.
Medical and interventional treatment are therefore comple-
mentary and not competing treatment options in patients
with hypertrophic cardiomyopathy and obstruction. Possi-
ble complications and unknown long-term effects of
PTSMA mandate careful patient selection. Furthermore,
intraprocedural echocardiographic monitoring with opti-
mization of the ablated septal area, reduction of peri-inter-
ventional complications, and improvement of acute as well
as mid-term hemodynamic results is necessary for achiev-
ing optimal interventional results. Finally, restriction of
PTSMA to few centers with large interventional experience
and knowledge of this relatively rare disease is of out-
standing importance.
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